Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention

Medicinal Research Reviews

Volumn 26, Issue 4, 2006, Pages 414-433

  Yeung, Kap Sun ^a   Yamanaka, Gregory A ^a   Meanwell, Nicholas A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

4,3 hydrophobic heptad repeats; Angiotensin converting enzyme 2; Antigenic determinants; Entry inhibitors; Monoclonal antibodies; Severe acute respiratory syndrome coronavirus; Spike protein

Indexed keywords

ANTIVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; EPITOPE; GLYCOPROTEIN; INTERFERON; LOPINAVIR PLUS RITONAVIR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDASE; PROTEINASE K; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS PROTEIN; VIRUS SPIKE PROTEIN;

CIRCULAR DICHROISM; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; HOST CELL; HUMAN; HYDROPHOBICITY; IN VIVO STUDY; NONHUMAN; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SURFACE PLASMON RESONANCE; VIRUS CELL INTERACTION; X RAY CRYSTALLOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; INHIBITORY CONCENTRATION 50; MEMBRANE GLYCOPROTEINS; MODELS, CHEMICAL; MODELS, GENETIC; MODELS, MOLECULAR; PEPTIDYL-DIPEPTIDASE A; PROTEIN STRUCTURE, TERTIARY; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS;

EID: 33745304779     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20055     Document Type: Review

References (102)

1. World Health Organization. www.who.int/iopics/sars/en
2. For an excellent summary of the various aspects of SARS see Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature Med 2004;10:S88-S97.
3. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen M-H, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TCT, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Günther S, Osterhaus ADME, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-1399.
4. Marra MA, Jones SJM, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YSN, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Sinailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. The genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-1404.
5. Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LLM, Guan Y, Rozanov M, Spaan WJM, Gorbalenya AE. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 2003;331:991-1004.
6. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk H-D, Rappuoli R. SARS-beginning to understand a new virus. Nat Rev Microbiol 2003;1:209-218.
7. Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol 2004;7:412-419.
8. Cínatl J, Jr., Michaelis M, Hoever G, Preiser W, Doerr HW. Development of anti-viral therapy for severe acute respiratory syndrome. Antiviral Res 2005;66:81-97.
9. Enserink M. One year after outbreak, SARS virus yields some secrets. Science 2004;304:1097.
10. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003;1614:36-50.
11. Ng ML, Tan SH, See EE, Ooi EE, Ling AE. Early events of SARS coronavirus in Vero cells. J Med Virol 2003;71:323-331.
12. For earlier review and highlight on SARS CoV S protein see: Hofmann H, Pöhlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol 2004;12:466-472, and ref. 13.
13. Xiao X, Dimitrov DS. The SARS-CoV S glcoprotein. Cell Mol Life Sci 2004;61(19-20):2428-2430.
14. Potential anti-SARS CoV approaches based on other viral targets see: Holmes KV. SARS coronavirus: A new challenge for prevention and therapy. J Clin Invest 2003;111:1605-1609, and ref. 15 and 16.
15. Davidson A, Siddell S. Potential for antiviral treatment of severe acute respiratory syndrome. Curr Opin Infect Dis 2003;16:565-571.
16. Shigeta S, Yamase T. Current status of anti-SARS agents. Antiviral Chem Chemother 2005;16:23-32.
17. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454.
18. Tripet B, Howards MW, Jobling M, Holmes RK, Hodges RS. Structural characterization of the SARS-coronavirus spike protein fusion core. J Biol Chem 2003;279:20836-20849.
19. Lin S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. Interaction between heptad repeat 1 and 2 regions in the spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004;363:938-947.
20. Bosch BJ, Martina BEE, van der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJR, de Groot R, Osterhaus ADME, Rottier PJM. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci USA 2004;101:8455-8460.
21. Ingallinella P, Bianchi E, Finotto M, Cantoni G, Eckert DM, Supckar VM, Bruckmann C, Carfi A, Pessi A. Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci USA 2004;101:8709-8714.
22. Xu Y, Zhu J, Liu Y, Lou Z, Yuan F, Liu Y, Cole DK, Ni L, Su N, Qin L, Li X, Bai Z, Bell JI, Pang H, Tien P, Gau GF, Rao Z. Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry 2004;43:14064-14071.
23. Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P, Gao GF. Following the rule: Formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem Biophys Res Commun 2004;319:283-288.
24. Bosch BJ, van der Zee R, de Han CAM, Rottier PJM. The cornonavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. J Virol 2003;77:8801-8811,
25. Xu Y, Liu Y, Lou Z, Qin L, Li X, Bai Z, Pang H, Tien P, Gao GF, Rao Z. Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem 2004;279:30514-30522.
26. Eckert DM, Kim PS. Mechanism of viral membrane fusion and its inhibition. Annu Rev Biochem 2001;70:777-810.
27. Zhao X, Singh M, Malashkevich VN, Kim PS. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci USA 2000;97:14172-14177.
28. Baker KA, Dutch RE, Lamb RA, Jardetzky TS. Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 1999;3:309-319.
29. Guillén J, Pérez-Berná AJ, Moreno MR, Villalaín J. Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: Implications for the viral fusion mechanism. J Virol 2005;79:1743-1752.
30. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS. The SARS-CoV S glycoprotein: Expression and functional characterization. Biochem Biophys Res Commun 2003;312:1159-1164.
31. Song HC, Seo M-Y, Stadler K, Yoo BJ, Choo Q-L, Coates SR, Uematsu Y, Harada T, Greer CE, Polo JM, Pileri P, Eickmann M, Rappuoli R, Abrigmini S, Houghton M, Han JH. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol 2004;78:10328-10335.
32. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severs acute respiratory syndrome-associated coronavirus (SARS CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA 2004;101:4240-4245.
33. Sainz BJ, Rausch JM, Gallaher WR, Garry RF, Wimley WC. Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J Virol 2005;79:7195-7206.
34. Wu XD, Shang B, Yang RF, Yu H, Ma ZH, Shen X, Ji YY, Lin Y, Wu YD, Lin GM, Tian L, Gan XQ, Yang S, Jiang WH, Dai EH, Wang XY, Jiang HL, Xie YH, Zhu XL, Pei G, Li L, Wu JR, Sun B. The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells. Cell Res 2004;14:400-406.
35. Chou T-HW, Wang S, Sakhatskyy PV, Mboudoudjeck I, Lawrence JM, Huang S, Coley S, Yang B, Li J, Zhu Q, Lu S. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2005;334:134-143.
36. Wang S, Chou T-HW, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 2005;79:1906-1910.
37. Sainz B, Jr., Rausch JM, Gallaher WR, Garry RF, Wimley WC. The aromatic domain of the coronavirus class I viral fusion protein induces membrane permeabilization: Putative role during viral entry. Biochemistry 2005;44:947-958.
38. Chang KW, Sheng YW, Gombold JL. Coronavirus-induced membrane fusion requires the cysteine-rich domain in the spike protein. Virology 2000;269:212-224.
39. Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, Qiu S, Bunzel RJ, Huang G, Mishra V, Voss TG, Kimberly R, Luo M. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 2004;78:7217-7226.
40. Yang Z-Y, Huang Y, Ganesh L, Leung K, Kong W-P, Schwartz O, Subbarao K, Nabel GJ. pH-Dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004;78:5642-5650.
41. Hofmann H, Hattermann K, Marzi A, Gramberg T, Geier M, Krumbiegel M, Kuate S, Uberla K, Niedrig M, Poehlmann S. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004;78:6134-6142.
42. Nie Y, Wang P, Shi X, Wang G, Chen J, Zheng A, Wang W, Wang Z, Qu X, Luo M, Tan L, Song X, Yin X, Chen J, Ding M, Deng H. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem Biophys Res Commun 2004;321:994-1000.
43. Han DP, Kim HG, Kim YB, Poon LLM, Cho MW. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 2004;326:140-149.
44. Zhang Q, Cui J, Huang X, Zheng H, Huang J, Fang L, Li K, Zhang J. The life cycle of SARS coronavirus in Vero E6 cells. J Med Virol 2004;73:332-337.
45. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005;308:1643-1645.
46. Supekar VM, Bruckmann C, Ingallinella P, Bianchi E, Pessi A, Carfi A. Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc Natl Acad Sci USA 2004;101:17958-17963.
47. Duquerroy S, Vigouroux A, Rottier PJM, Rey FA, Bosch BJ. Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein. Virology 2005;335:276-285.
48. Xu Y, Lou Z, Liu Y, Pang H, Tien P, Gao GF, Rao Z. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 2004;279:49414-49419.
49. Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. Suppression of SARS-CoV by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun 2004;319:746-752.
50. Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, Zhang H, Luo H, Zhu L, Jiang P, Chen L, Shen Y, Luo M, Zuo G, Hu J, Duan D, Nie Y, Shi X, Wang W, Hail Y, Li T, Liu Y, Ding M, Deng H, Xu X. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 2004;78:11334-11339.
51. Cianci C, Langley DR, Dischino DD, Sun Y, Yu K-L, Stanley A, Roach J, Li Z, Dalterio R, Colonno R, Meanwell NA, Krystal M. Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusion. Proc Natl Acad Sci USA 2004;101:15046-15051.
52. Cianci C, Meanwell N, Krystal M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother 2005;55:289-292.
53. Cianci C, Genovesi EV, Lamb L, Medina I, Yang Z, Zadjura L, Yang H, D'Arienzo C, Sin N, Yu K-L, Combrink K, Li Z, Colonno R, Meanwell N, Clark J, Krystal M. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother 2004;48:2448-2454.
54. Wang P, Chen J, Zheng A, Nie Y, Shi X, Wang W, Wang G, Luo M, Liu H, Tan L, Song X, Wang Z, Yin X, Qu X, Wang X, Qing Y, Ding M, Deng H. Expression cloning of functional receptor used by SARS coronavirus. Biochem Biophys Res Commun 2004;315:439-444.
55. For an earlier highlight see: Turner AJ, Hiscox JA, Hooper NM. ACE2: From vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004;25:291-294.
56. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. J Biol Chem 2000;275:33238-33243.
57. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin 1 to angiotensin 1-9. Circ Res 2000;87:e1-e9.
58. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-828.
59. To KF, Tong JHM, Chan PKS, Au FWL, Chim SSC, Chan KCA, Cheung JLK, Liu EYM, Tse GMK, Lo AWI, Lo YMD, Ng HK. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: An in-situ hydridization study of fatal cases. J Pathol 2004;202:157-163.
60. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637.
61. 50 of 41.6 μM.
62. Hu H, Li L, Kao RY, Kou B, Wang Z, Zhang L, Zhang H, Hao Z, Tsui WH, Ni A, Cui L, Fan B, Guo F, Rao S, Jiang C, Li Q, Sun M, He W, Liu G. Screening and identification of linear B-cell epitopes and entry-blocking peptides of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J Comb Chem 2005;7:648-656.
63. Babcock GJ, Esshaki DJ, Thomas WD, Jr., Ambrosino DM. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 2004;78:4552-4560.
64. Xiao X, Feng Y, Chakraborti S, Dimitrov D. Oligomerization of the SARS-CoV S glycoprotein: Dimerization of the N-terminus and trimerization of the cctodomain. Biochem Biophys Res Commun 2004;322:93-99.
65. Moore MJ, Dorfman T, Li W, Wong SK, Li Y, Kuhn JH, Coderre J, Vasilieva N, Han Z, Greenough TC, Farzan M, Choe H. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol 2004;78:10628-10635.
66. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GF, Gramberg T, Pöhlmann S. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin-converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004;319:1216-1221.
67. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, St. Clair Tallarico A, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that block receptor association. Proc Natl Acad Sci USA 2004;101:2536-2541.
68. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, Patane MA, Pantoliano MW. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 2004;279:17996-18007.
69. Spiga O, Bernini A, Ciutti A, Chiellini S, menciassi N, Finetti F, Causarono V, Anselmi F, Prischi F, Niccolai N. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem Biophys Res Commun 2003;310:78-83.
70. Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun 2004;314:235-241.
71. Zhang Y, Zheng N, Hao P, Cao Y, Zhong Y. A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2. Comput Biol Chem 2005;29:254-257.
72. www.Progenics.com
73. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJuses E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, Shanahan WR, Jr. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type I. J Infect Dis 2004;189:286-291.
74. Dales NA, Could AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD, Patane MA. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 2002;124:11852-11853.
75. Note added in Proof: It has been recently shown that MLN-4760 did not inhibit the binding of the S1 domain to ACE2, Li W, Zhang C. Sui J, Kuhn JH, Moore MJ, Luo S, Wong S-K, Huang I-C, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005;24:1634-1643.
76. Selective peptide inhibitors of ACE2: Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, Sanya I, Parry T, Kent R, Enright J, Wu Q, Conley G, DeOliveira D, Morganelli L, Ducar M, Wescott CR, Ladner RC. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 2003;278:15532-15540.
77. Kao RY, Tsui WHW, Lee TSW, Tanner JA, Watt RM, Huang J-D, Hu L, Chen G, Zhang L, He T, Chan K-H, Tse H, To APC, Ng LWY, Wong BCW, Tsoi H-W, Yang D, Ho DD, Yuen K-Y. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 2004;11:1293-1299.
78. To KF, Lo AWI. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): The tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 2004;203:740-743.
79. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, Thomas WD Jr, Thackray LB, Young MD, Mason RJ, Ambrosino DM, Wentworth DE, DeMartini JC, Holmes KV. CD290L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA 2004;101:15748-15753.
80. Lu L, Manopo I, Leung BP, Chug HH, Ling AE, Chee LL, Ooi EE, Chan S-W, Kwang JJ. Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol 2004;42:1570-1576.
81. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: Implication for the developing SARS diagnostics and vaccines. J Immunol 2004;173:4050-4057.
82. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine. Biochem Biophys Res Commun 2004;324:773-781.
83. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174:4908-4915.
84. van der Brink EN, ter Meulen J, Cox F, Jongeneelen MAC, Thijsse A, Throsby M, Marissen WE, Rood PML, Bakker ABH, Gelderblom HR, Martina BE, Osterhaus ADME, Preiser W, Doerr HW, de Kruif J, Goudsmit J. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of emerging severe acute respiratory syndrome coronaviruses. J Virol 2005;79:1635-1644.
85. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 2005;79:5900-5906.
86. Greenough TC, Babcock GJ, Roberts A, Herandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbaruo K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 2005;191:507-514.
87. Hua R, Zhou Y, Wang Y, Hua Y, Tong G. Identification of two antigenic epitopes on SARS-CoV spike protein. Biochem Biophys Res Commun 2004;319:929-935.
88. Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen K-Y, Ho DD. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005;79:2678-2688.
89. Yang Z-Y, Kong W-P, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561-564.
90. Zhong X, Yang H, Guo Z-F, Sin W-YF, Chen W, Xu J, Fu L, Wu J, Mak C-KG, Cheng C-SS, Yang Y, Cao S, Wong T-Y, Lai S-T, Xie Y, Guo Z. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J Virol 2005;79:3401-3408.
91. Zhang H, Wang G, Li J, Nie Y, Shi X, Kian G, Wang W, Yin A, Zhao Y, Qu X, Ding M, Deng H. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 2004;78:6938-6945.
92. Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, Tan THP, Chou C-F, Loh CB, Wang S, Fu J, Yang X, Lim SG, Hong W, Tan YJ. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induces neutralizing antibodies: Implications for the development of vaccines and antiviral agents. J Virol 2005;79:3289-3296.
93. Zhi Y, Kobinger GP, Jordan H, Suchma K, Weiss SR, Shen H, Schumer G, Gao G, Boyer JL, Crystal RG, Wilson JM. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology 2005;335:34-45.
94. Wang Y-D, Sin W-YF, Xu G-B, Yang H-H, Wong T-Y, Pang X-W, He X-Y, Zhang H-G, Ng JNL, Cheng C-SS, Ju J, Meng L, Yang R-F, Lai S-T, Guo Z-H, Xie Y, Chen W-F. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol 2005;79:5612-5618.
95. + T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 2004;104:200-206.
96. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh W-J, Zaki S, Murphy BR. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Viol 2004;78:3572-3577.
97. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappouli R, Lanzavecchia A. An efficient method to make monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 2004;10:871-875.
98. ter Meulen J, Bakker ABH, van der Brink EN, Wevering GJ, Martina BEE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus ADME. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004;363:2139-2141.
99. Yang Z-Y, Werner HC, Kong W-P, Leung K, Traggiai E, Lanzavecchia A, Nabel G. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005;102:797-801.
100. An endosomal protease cathepsin L dependent entry for SARS CoV has been identified. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005;102:11876-11881.
101. Enhancement of SARS CoVentry by cell surface pmteases has also been reported. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci USA 2005;102:12543-12547.
102. The x-ray crystal structure of the S1 RBD complexed with ACE2 has been determined. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005;309:1864-1868.